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Endoscopy showed resolution of GvHD in the colon and duode-
num. Video visualization was performed to evaluate the distal small
bowel using the M2A endoscopic capsule by Given Imaging. The
duodenum and colonic mucosa appeared normal, but the jejunum
and ileum had severe diffuse bleeding ulcerations. The video cap-
sule is 11mm 26mm, weighs less than 4 grams, has a ﬁeld of view
of 140 degrees, and can detect lesions less than 0.1mm. The camera
takes pictures for 8 hours and generates approximately 57,000
images at 2 frames per second. Contraindications include suspected
obstruction or stricture, presence of a cardiac pacemaker, or a
swallowing disorder. Video visualization gives valuable informa-
tion on the status of the distal small bowel that cannot be obtained
by ﬁberoptic endoscopy and may aid in evaluation of GvHD
following allogeneic BMT.
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SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR: ENBREL (ETANER-
CEPT) FOR THE TREATMENT OF IDIOPATHIC PNEUMONIA SYNDROME
FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION
Yanik, G.A.1, Uberti, J.P.1, Ferrara, J.L.M.1, Levine, J.E.1, Hutchin-
son, R.J.1, Ho, V.T.2, Cooke, K.R.1 1. University of Michigan Medical
Center, Ann Arbor, MI; 2. Dana-Farber Cancer Institute, Boston, MA
Non-infectious lung injury is as a frequent and severe complica-
tion of allogeneic bone marrow transplantation (BMT). In the
acute setting, a diffuse non-infectious process termed Idiopathic
Pneumonia Syndrome (IPS) may occur. Despite advances in sup-
portive care and the use of high dose steroids, mortality from IPS
remains unacceptably high ( 70%). Etanercept is a soluble tumor
necrosis factor (TNF) receptor, consisting of two soluble p75 TNF
receptors fused to the Fc portion of a human IgG1. A trial exam-
ining etanercept in the treatment of IPS following allogeneic
transplant has now been undertaken. Fourteen patients (median 18
yrs, range 1-60 yrs), each meeting the diagnostic criteria for IPS
were treated. Broncho-alveolar lavage (BAL) specimen were ob-
tained pre and post therapy, undergoing analysis for both infec-
tious pathogens (viral, bacterial, fungal, PCP, AFB) and for inﬂam-
matory cytokine markers (TNF, TNFR1, sCD-14, LBP, and
MCP-1). Patients in whom the pre-therapy BAL was positive for a
potential pathogen (by speciﬁc stain or culture) were ineligible for
therapy. Etanercept was administered subcutaneously at a dose of
0.4 mg/kg (maximum dose 25 mg) twice weekly, for a maximum of
8 doses. All patients required supplemental oxygen at therapy
onset, with seven patients requiring mechanical ventilation. Etan-
ercept therapy was initiated a median of 17 days (range 11-87 days)
post transplant. Results: Therapy was well tolerated, with no
infusion related reactions. Eight of 14 patients had a complete
response, deﬁned as the ability to withdraw completely from sup-
plemental oxygen support. In those responding, the median time to
complete response was 7 days (range 3-18 days), and the median
time to normalization of radiographic ﬁndings was 6 days (range
2-10 days). Two other patients had a signiﬁcant reduction in their
FiO2 requirement during therapy. Three patients died while on
therapy, from progressive organ dysfunction. Post therapy BAL
ﬂuid analysis noted a signiﬁcant reductions in all inﬂammatory
cytokines tested, including TNFa, TNFR1, sCD14, LBP and
MCP-1 (Table below). Conclusion: Etanercept therapy was well
tolerated, with minimal toxicity and favorable response in patients
with IPS post allogeneic transplant. The clinical and biochemical
responses seen with therapy support a mechanistic role for TNFa
in the pathogenesis of this disorder. Further trials, investigating the
responsiveness of IPS to etanercept therapy are warranted.
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NEUROLEPTIC MALIGNANT SYNDROME FOLLOWING STEM CELL
TRANSPLANTATION
Craig, M., Ericson, S., Schunn, G., Beall, C.L. Mary Babb Randolph
Cancer Center, West Virginia University, Morgantown, WV
Neuroleptic malignant syndrome (NMS) is a rare disorder pre-
senting with hyperthermia, muscle rigidity, autonomic instability,
and altered consciousness. Although NMS is usually associated
with antipsychotic medications, it has also been described in pa-
tients receiving antiemetics. The estimated incidence in susceptible
populations is about 0.2%, with an associated mortality rate 10-
20%. Three cases of NMS following bone marrow or peripheral
blood stem call transplantation have been described in the medical
literature. We present an additional patient for review. A 51 year-
old female underwent autologous peripheral blood stem cell trans-
plantation for IgA kappa multiple myeloma with high dose mel-
phalan. She achieved engraftment on day 14. Her post-
transplantation course was complicated by persistent nausea and
vomiting requiring treatment with prochlorperazine or prometh-
azine. On day 20, she developed fever of 39.4°C, labile blood
pressure, elevated pulse, and delirium. Antimicrobials were begun
for presumed sepsis. Cultures were negative. By day 21, her
temperature had climbed to 40.9°C, delirium continued, and mus-
cle rigidity developed, with an elevation in CK. She had a gener-
alized tonic-clonic seizure. NMS was diagnosed based on her
clinical scenario and all antiemetics were discontinued. Dantrolene
sodium was initiated IV. Response occurred with resolution of
temperature, decreased muscle rigidity, and improved mental sta-
tus within 24 hours. Previous reports of NMS following transplan-
tation include 2 cases diagnosed 9 and 11 days following autolo-
gous transplantation for liposarcoma and breast cancer (Garrido
SM, et al. Bone Marrow Transplantation 1998;21:427-8). Another
was seen 6 days after allogeneic transplant for AML (Onose M, et
al. Bone Marrow Transplantation 2002;29:803-4). Two had re-
ceived haloperidol, while another received prochlorperazine and
droperidol. All three responded to discontinuing offending medi-
cations and supportive care. There were no deaths. The recogni-
tion of NMS in the post-transplantation setting is confounded by
multiple etiologies for fever and delirium in these patients. The
pathology of the disorder is felt to relate to dopamine blockade.
Initial treatments involve stopping inciting medications and sup-
portive care. Pharmacological interventions such as bromocriptine,
dantrolene sodium, and benzodiazepines should be used to shorten
duration of symptoms and improve survival.
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TACROLIMUS CONVERSION FROM INTRAVENOUS (I.V.) TO ORAL (P.O.)
IN ALLOGENEIC STEM CELL TRANSPLANTATION
Zimmerman, R.L., Petersen, K.A., Hardiman, P.S., Davis, T.L.,
Lynch, J.C., Devetten, M.P. University of Nebraska Medical Center,
Omaha, NE
Tacrolimus (FK506) is commonly used in allogeneic stem cell
transplantation (SCT) to prevent rejection and graft-versus-host
disease. Dosing recommendations are mostly based on studies
performed in solid-organ transplant recipients. The package insert
recommends a conversion rate of 1:4 when changing from the
intravenous to the oral formulation. We retrospectively reviewed
tacrolimus levels and toxicity in 32 patients who underwent allo-
geneic SCT between July 2001 and June 2003 using the package
insert recommended conversion rate. All patients started tacroli-
mus on day -1 at a dose of 0.03 mg/kg actual body weight by
continuous IV infusion. Levels were drawn peripherally on day1,
3, 5 and then biweekly. Target range for tacrolimus levels was
8-12 ng/mL. Conversion from IV to PO at a conversion rate of 1:4
occurred when patients could tolerate P.O. medication. Thirty-
two patients underwent alloSCT for a variety of hematologic
malignancies. Median age at the time of transplant was 43 year
(range 19-58), 78% underwent a MRD donor SCT, 3% a 5/6
MRD SCT, and 19% a MUD SCT, conditioning was Cy/TBI
(89%) or Bu/Cy2 (11%). Ninety-three percent of patients with
available data required at least one IV dose reduction, the median
day of IV to PO conversion was11 (range7-25). The median
Table. BAL Fluid: Mean Values Pre- and Post-Etanercept Therapy
n
TNF
(pg/mL)
TNFR1
(ng/mL)
sCD-14
(ng/mL)
LBP
(ng/mL)
MCP-1
(ng/mL)
Control-A 3 5.2 (0-16) .02 (.02-.03) 0 (0) 0 (0) 0.04 (.015-0.07)
Control-B 10 5.4 (0-23) .11 (.02-.37) 1.9 (0-8.8) 0 (0) 0.28 (0.02-1.0)
IPS pre-Tx 7 93 (0-500) .86 (.08-1.5)* 82.6 (0-250)* 331 (0-1000)* 20 (0.6-73.9)
IPS post-Tx 5 16 (10-23) .18 (.1-0.36)† 3.0 (0-6.2) 0 (0) 0.07 (.05-0.1)†
Controls were (A) a group of healthy volunteers or (B) transplant patients without IPS.
*P .05, IPS pre-tx versus Control-B, †P .05, IPS post-tx versus IPS pre-therapy.
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initial PO dose was 0.08 mg/kg (range 0.04-0.18) and the median
conversion ratio was 0.26 (range 0.12-0.4). Median initial tacroli-
mus level after conversion was 16.9 ng/mL (range 5.3-52.4).
Twenty-seven patients (93%) required a reduction in their PO
dosing, only two patients immediately achieved a stable PO dose
(deﬁned as two consecutive tacrolimus levels within the therapeutic
range). Nine patients (31%) developed a creatinine level greater
than twice their baseline level, eleven patients (38%) required
intervention to lower potassium, and three patients (10%) devel-
oped tremors. No irreversible complications were encountered.
We conclude that the presently recommended conversion rate
frequently results in toxic serum levels associated with mild renal
insufﬁciency and other adverse effects. We have changed our
conversion rate from 1:4 to 1:2.
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PEDIATRIC PATIENTS BENEFIT FROM INTRAVENOUS BUSULFAN FOR
MYELOABLATION IN ALLOGENEIC HSCT
Fisher, V.L., Nieder, M.L., Malbassi, C., Halliday, E.R., Wiersma,
S.R., Reed, M. Rainbow Babies and Children’s Hospital/Case Western
Reserve University School of Medicine, Cleveland, OH
Oral busulfan is a component of standard preparative regimens
used for myeloablation in HSCT. In children, complications of
oral administration include emesis, frequent need for NG tube
insertion and irritability because of food restriction around the
time of dose administration. Plasma levels must be monitored, and
are often unpredictable, resulting in the need to adjust doses and
repeat levels. We administered intravenous busulfan to eleven
children (aged 9 months to 15 years) who were undergoing HSCT
(cord, marrow PBSC) for malignant and non-malignant disorders.
Patients received IV busulfan according to the following protocol:
Intravenous busulfan was diluted in D5W or NS to a ﬁnal con-
centration of 0.5mg/ml. Busulfan is stable for 8 hours at room
temperature or up to 12 hours (in NS only) at 2-8 degrees celsius.
The IV tubing was primed with the busulfan solution and admin-
istered through a controlled-rate infusion pump. It was infused
over 2 hours. Pharmacokinetic (PK) sampling was obtained after
the ﬁrst dose at 2,3,4,5 6 hours.When PK information was needed
after subsequent doses, a baseline level was obtained just prior to
the infusion of the next dose. Pharmacokinetic evaluations were
performed after the ﬁrst dose on all patients and after dose 9 on
seven patients. Based on the Dose 1 results, adjustments were made
for only 3 of 11 patients. Patients received oral or IV ondansetron
and no emesis was reported for any of the 11 patients. No toxicities
were observed on any patients during the four day administration
of the IV busulfan. One patient died of sepsis on Day T 11; all
other patients engrafted. Except for moderate VOD in one patient,
no unexpected GVHD, relapse or other acute toxicities were ob-
served. For children undergoing HSCT, IV busulfan is easier to
administer, is more acceptable to patients and their families, pro-
vides more predictable plasma levels and is not associated with
more acute toxicity than oral busulfan. When busulfan is used at
our institution, the intravenous form has become the standard
preparation for children less than 18 years of age.
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SUCCESSFUL USE OF ORAL TACROLIMUS FOR GVH PROPHYLAXIS
DURING THE FIRST 100 DAYS POST HSCT
Nieder, M.L., Fisher, V.L., Danish, D., Halliday, E.M., Wiersma, S.R.
Rainbow Babies and Children’s Hospital/Case Western Reserve Univer-
sity School of Medicine, Cleveland, OH
Traditionally, intravenous cyclosporine or tacrolimus has been
used in the early post-transplant period for GVH prophylaxis. We
report on the use of oral tacrolimus on sixteen patients (aged 15
months to 18 years) who underwent allogeneic stem cell trans-
plants (cord, PBSC marrow) for a variety of malignant and non-
malignant disorders. All patients received oral glutamine (2
grams/m2 per dose BID) beginning on T -5. Day T -2 through T
100, patients received tacrolimus (0.1-0.2 mg/kg dose BID)
orally or via an NG tube. For small children, our hospital phar-
macy produced a tracolimus suspension. Trough tacrolimus blood
levels were obtained 12 hours after the 4th dose and ranged from
6-14.3 ng/mL. Dose adjustments were made when necessary and
14 of 16 patients completely avoided intravenous tacrolimus. Two
patients required IV tacrolimus for 4-6 days in total because of
persistent vomiting. Avoiding the use of IV tacrolimus reduced the
need for additional IV access, resulted in less hypertension and
signiﬁcantly decreased the cost of the transplant. We observed no
increase in graft failure, GVH, infections, relapse or mortality.
Renal tubular acidosis is commonly seen in these patients, who
often require oral sodium bicarbonate supplemenation. For 14/16
patients, renal tubular function returned to normal within 3
months after stopping the tacrolimus. Oral tacrolimus can safely be
given to transplant patients from the beginning of the transplant
and throughout the ﬁrst 100 days post-transplant.
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NAUSEA AND VOMITING IN PATIENTS RECEIVING HIGH DOSE CHEMO-
THERAPY FOLLOWED BY PERIPHERAL BLOOD STEM CELL TRANS-
PLANT IN AN OUTPATIENT SETTING
Paivanas, N.1, Malone, C.1, Spiros, A.R.1, Sheridan, M.J.2, Spira,
A.I.1, Orloff, G.J.1, Beveridge, R.A.1 1. Fairfax Stem Cell Transplant
Program INOVA Fairfax Hospital Cancer Center, Fairfax, VA; 2.
INOVA Fairfax Hospital, Fairfax, VA
Background: Nausea and vomiting (N/V) are signiﬁcant side
effects in patients receiving high-dose chemotherapy therapy
(HDC). We examined our institution’s experience with N/V, as
presented in HDC patients receiving peripheral blood stem cell
transplants (PBSCT) utilizing 3 speciﬁc conditioning regimens.
Methods: A retrospective chart review was conducted on twenty-
nine patients who received an autologous PBSCT within the past
two years. Data was gathered from a daily nursing N/V assessment
Table.
Age Diagnosis PREP
ANC > 500
on T 
Serious
Adverse
Events
15 CML Bu-Cy 12 None
13 Sickle Cell Bu-Cy-ATG 20 None
0.11 HLH Bu-Cy-VP-ATG 13 Sepsis
15 AML-CR1 Bu-Cy 15 Mild VOD
0.10 AML-CR1 Bu-Cy 16 Mod VOD
4 Osteopetrosis Bu-Cy 15 None
2 AML-CR1 Bu-Cy 11 None
2 Beta Thal Bu-Cy 17 None
13 Beta Thal Bu-Cy None Sepsis/Death
0.9 MDS Bu-Cy 13 None
8 Neutropenia Bu-Cy 15 None
Table. Patient Demographics
Age in
Years Diagnosis PREP
Acute
GVH
HSC
Source
Status at
Day 100
18 ALL-CR3 ARAC-Cy-TBI II MUD-PB Alive; Relapse
0.9 MDS Bu-Cy None MRD-BM Alive & Well
18 ALL-CR2 Cy-TBI None MUD-PB Alive; Graft
Failure
5 ALL-CR2 Cy-TBI None MRD-UCB Alive & Well
18 ALL-CR3 Cy-TBI II MUD-PB Alive & Well
14 ALL-CR1 ARAC-Cy-TBI None MUD-BM Alive & Well
2 Beta Thal Bu-Cy None MRD-BM Alive & Well
15 CML Bu-Cy None MRD-BM Alive & Well
8 ALL-CR1 Cy-TBI None MUD-PB Alive & Well
4 Osteopetrosis Bu-Cy None MRD-BM Alive & Well
12 CML Cy-TBI None MRD-PB Alive & Well
18 Severe AA Cy-ATG II MRD-PB Alive & Well
1 AML-CR1 Cy-TBI None MRD-PB Alive; Relapse
8 Neutropenia Bu-Cy None MUD-PB Alive & Well
8 ALL-CR1 Cy-TBI II MRD-PB Alive & Well
13 Beta Thal Bu-Cy NA MRD-BM Deceased
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